JP2018520685A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520685A5 JP2018520685A5 JP2018502133A JP2018502133A JP2018520685A5 JP 2018520685 A5 JP2018520685 A5 JP 2018520685A5 JP 2018502133 A JP2018502133 A JP 2018502133A JP 2018502133 A JP2018502133 A JP 2018502133A JP 2018520685 A5 JP2018520685 A5 JP 2018520685A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- seq
- nos
- strand
- monomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193997P | 2015-07-17 | 2015-07-17 | |
| US62/193,997 | 2015-07-17 | ||
| PCT/US2016/042694 WO2017015175A1 (en) | 2015-07-17 | 2016-07-17 | Compositions and agents against hepatitis b virus and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520685A JP2018520685A (ja) | 2018-08-02 |
| JP2018520685A5 true JP2018520685A5 (enExample) | 2019-03-28 |
| JP6924744B2 JP6924744B2 (ja) | 2021-08-25 |
Family
ID=57775056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502133A Expired - Fee Related JP6924744B2 (ja) | 2015-07-17 | 2016-07-17 | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20170016000A1 (enExample) |
| EP (1) | EP3325097B1 (enExample) |
| JP (1) | JP6924744B2 (enExample) |
| CN (1) | CN108136206B (enExample) |
| AU (1) | AU2016296592B2 (enExample) |
| CA (1) | CA2996722A1 (enExample) |
| TW (1) | TWI761311B (enExample) |
| WO (1) | WO2017015175A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2726613T (pt) | 2011-06-30 | 2018-10-26 | Arrowhead Pharmaceuticals Inc | Composições e métodos para inibição da expressão de genes do vírus da hepatite b |
| CN115957337A (zh) * | 2015-08-07 | 2023-04-14 | 箭头药业股份有限公司 | 乙型肝炎病毒感染的RNAi疗法 |
| AU2017285350A1 (en) | 2016-06-17 | 2018-12-20 | F. Hoffmann-La Roche Ag | Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection |
| JOP20190015A1 (ar) | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| KR20200030594A (ko) | 2017-10-16 | 2020-03-20 | 에프. 호프만-라 로슈 아게 | B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자 |
| CN118291456A (zh) | 2017-12-01 | 2024-07-05 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105414A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| HRP20250277T1 (hr) | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| JP7360716B2 (ja) | 2017-12-01 | 2023-10-13 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| CN110944675B9 (zh) | 2017-12-01 | 2024-08-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN110959011B (zh) | 2017-12-29 | 2023-03-28 | 苏州瑞博生物技术股份有限公司 | 缀合物及其制备方法和用途 |
| MA52661A (fr) | 2018-04-05 | 2021-02-17 | Centre Leon Berard | Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b |
| EP3802827A4 (en) * | 2018-05-16 | 2022-08-03 | Alnylam Pharmaceuticals, Inc. | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT |
| WO2019240504A1 (en) * | 2018-06-12 | 2019-12-19 | Am Sciences Co., Ltd. | Modified oligonucleotides for inhibition of target gene expression |
| WO2019240503A1 (ko) * | 2018-06-12 | 2019-12-19 | 주식회사 에이엠사이언스 | B형 간염 예방 또는 치료용 조성물 |
| TWI862501B (zh) | 2018-07-03 | 2024-11-21 | 瑞士商赫孚孟拉羅股份公司 | 用於調制 Tau 表現之寡核苷酸 |
| BR112021000538A2 (pt) | 2018-07-13 | 2021-04-06 | F. Hoffmann-La Roche Ag | Oligonucleotídeos para modular a expressão de rtel1 |
| WO2020038377A1 (zh) * | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| JP7376952B2 (ja) | 2018-09-30 | 2023-11-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | ｓｉＲＮＡ複合体及びその調製方法と使用 |
| JP7507495B2 (ja) | 2018-12-28 | 2024-06-28 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CN113227376B (zh) | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| JP7610848B2 (ja) | 2019-05-22 | 2025-01-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| CN113286888B (zh) | 2019-05-22 | 2023-12-22 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113795582B (zh) | 2019-05-24 | 2024-05-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN110218728A (zh) * | 2019-06-28 | 2019-09-10 | 厦门甘宝利生物医药有限公司 | 一种新化合物及其应用 |
| WO2021107097A1 (ja) * | 2019-11-28 | 2021-06-03 | 株式会社ボナック | Ｂ型肝炎治療用核酸分子 |
| JP2023506540A (ja) | 2019-12-19 | 2023-02-16 | エフ． ホフマン－ラ ロシュ エージー． | Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用 |
| WO2021122921A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of cops3 inhibitors for treating hepatitis b virus infection |
| WO2021122910A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of sbds inhibitors for treating hepatitis b virus infection |
| CN114867856A (zh) | 2019-12-19 | 2022-08-05 | 豪夫迈·罗氏有限公司 | Saraf抑制剂用于治疗乙型肝炎病毒感染的用途 |
| JP7634542B2 (ja) | 2019-12-19 | 2025-02-21 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用 |
| AR122731A1 (es) | 2020-06-26 | 2022-10-05 | Hoffmann La Roche | Oligonucleótidos mejorados para modular la expresión de fubp1 |
| CA3187388A1 (en) * | 2020-07-27 | 2022-02-03 | Jin Hong | Hbv binding oligonucleotides and methods of use |
| JP2023538630A (ja) | 2020-08-21 | 2023-09-08 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用 |
| CN116472063A (zh) * | 2020-11-06 | 2023-07-21 | 阿布特斯生物制药公司 | 包含经修饰的siRNA的靶向性偶联物 |
| KR102798766B1 (ko) * | 2020-12-18 | 2025-04-23 | 올릭스 주식회사 | HBV 발현을 억제하는 RNAi 제제 및 이의 용도 |
| US20240309366A1 (en) * | 2020-12-31 | 2024-09-19 | Arcturus Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
| CN114767704B (zh) * | 2021-01-21 | 2024-06-14 | 圣诺制药公司 | 一种能够靶向乙型肝炎病毒的药物构造及药物组合物 |
| TW202246500A (zh) | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸 |
| CN119095603A (zh) | 2021-12-17 | 2024-12-06 | 豪夫迈·罗氏有限公司 | 用于调节rtel1和fubp1的寡核苷酸的组合 |
| CN115267193B (zh) * | 2022-09-20 | 2022-12-27 | 北京大学 | 用于判断生物样本中HBsAg来源的方法及系统和用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| EP1505942B1 (en) | 2002-05-10 | 2008-08-13 | Tekmira Pharmaceuticals Corporation | Pathogen vaccines and methods for using the same |
| US20070027099A1 (en) * | 2003-05-19 | 2007-02-01 | Lin Marie C | Gene therapy of HBV infection via adeno-associated viral vector mediated long term expression of small hairpin RNA (shRNA) |
| US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| DK2270162T3 (en) | 2003-06-12 | 2019-01-21 | Alnylam Pharmaceuticals Inc | PRESERVED HBV AND HCV SEQUENCES USED FOR GEN-SILENCING |
| CN1981033A (zh) | 2004-05-19 | 2007-06-13 | 墨尔本保健公司 | 乙型肝炎的治疗、预防和诊断试剂 |
| EP1796732B1 (en) | 2004-10-01 | 2013-10-30 | Novartis Vaccines and Diagnostics, Inc. | Modified small interfering rna molecules and methods of use |
| US8765704B1 (en) | 2008-02-28 | 2014-07-01 | Novartis Ag | Modified small interfering RNA molecules and methods of use |
| KR20100060018A (ko) | 2005-03-09 | 2010-06-04 | 재단법인 목암생명공학연구소 | 작은 간섭 ｒｎａ 및 이를 포함하는 ｂ형 간염 바이러스 치료용 약학 조성물 |
| US20090226525A1 (en) | 2007-04-09 | 2009-09-10 | Chimeros Inc. | Self-assembling nanoparticle drug delivery system |
| NZ580712A (en) | 2007-05-22 | 2011-12-22 | Marina Biotech Inc | Hydroxymethyl substituted rna oligonucleotides and rna complexes containing acyclic monomers |
| US20100209491A1 (en) | 2007-09-17 | 2010-08-19 | Mogam Biotechnology Research Institute | Method for enhancing serum stability and lowering immune response of sirna down-regulating gene expression of hbv or hcv |
| WO2009106999A2 (en) | 2008-02-28 | 2009-09-03 | Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | Hollow nanoparticles and uses thereof |
| US20100015708A1 (en) | 2008-06-18 | 2010-01-21 | Mdrna, Inc. | Ribonucleic acids with non-standard bases and uses thereof |
| CA2744093A1 (en) | 2008-12-03 | 2010-06-10 | Marina Biotech, Inc. | Una oligomer structures for therapeutic agents |
| ES2651308T3 (es) | 2009-10-16 | 2018-01-25 | Glaxo Group Limited | Inhibidores antisentido de HBV |
| RU2745848C2 (ru) | 2010-08-17 | 2021-04-01 | Сирна Терапьютикс, Инк. | ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) |
| SI3505528T1 (sl) | 2011-04-21 | 2021-04-30 | Glaxo Group Limited | Modulacija izražanja virusa hepatitisa B (HBV) |
| PT2726613T (pt) | 2011-06-30 | 2018-10-26 | Arrowhead Pharmaceuticals Inc | Composições e métodos para inibição da expressão de genes do vírus da hepatite b |
| CA2853609A1 (en) | 2011-10-28 | 2013-05-02 | University Of The Witwatersrand, Johannesburg | Inhibition of viral gene expression |
| WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| CN104837501B (zh) | 2012-08-30 | 2018-11-02 | 里普利科股份有限公司 | 治疗乙型肝炎及丁型肝炎感染的方法 |
| CN105103603A (zh) | 2012-12-05 | 2015-11-25 | 诺基亚通信公司 | 用于流量导向的方法和网络元件 |
| WO2015050871A2 (en) * | 2013-10-04 | 2015-04-09 | Novartis Ag | Organic compounds to treat hepatitis b virus |
| CN110003066B (zh) | 2013-11-18 | 2021-09-03 | 阿克丘勒斯治疗公司 | 用于rna递送的可电离的阳离子脂质 |
| GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| EP3151839A4 (en) | 2014-06-06 | 2018-02-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds |
| US10415037B2 (en) | 2014-10-02 | 2019-09-17 | Arbutus Biopharma Corporation | Compositions and methods for silencing hepatitis B virus gene expression |
-
2016
- 2016-07-17 JP JP2018502133A patent/JP6924744B2/ja not_active Expired - Fee Related
- 2016-07-17 CN CN201680053632.1A patent/CN108136206B/zh not_active Expired - Fee Related
- 2016-07-17 WO PCT/US2016/042694 patent/WO2017015175A1/en not_active Ceased
- 2016-07-17 CA CA2996722A patent/CA2996722A1/en active Pending
- 2016-07-17 US US15/212,279 patent/US20170016000A1/en not_active Abandoned
- 2016-07-17 AU AU2016296592A patent/AU2016296592B2/en not_active Ceased
- 2016-07-17 EP EP16828341.4A patent/EP3325097B1/en not_active Not-in-force
- 2016-09-10 TW TW105129484A patent/TWI761311B/zh not_active IP Right Cessation
-
2018
- 2018-08-30 US US16/117,994 patent/US10961535B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108136206B (zh) | 抗乙型肝炎病毒的组合物和药剂及其用途 | |
| JP7442574B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| ES2988612T3 (es) | Agentes de ARNi para la infección por el virus de la hepatitis B | |
| AU2011263642B2 (en) | Method for selective oligonucleotide modification | |
| JP2016502858A5 (enExample) | ||
| CN115516092A (zh) | 血管生成素样3(ANGPTL3)的siRNA及其用途 | |
| JP2019504112A5 (enExample) | ||
| JP2018519835A5 (enExample) | ||
| JP2023158214A (ja) | Ｈｉｆ２αの遺伝子発現を阻害する組成物及び方法 | |
| JP2017538679A5 (enExample) | ||
| HRP20191232T1 (hr) | Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina) | |
| CN113507920A (zh) | 用于乙型肝炎病毒感染的RNAi剂 | |
| JP2019533472A5 (enExample) | ||
| WO2016115490A1 (en) | Compounds and methods for modulation of dux4 | |
| RU2020115761A (ru) | МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В | |
| RU2014121304A (ru) | Ингибирование экспрессии вирусных генов | |
| RU2020135289A (ru) | Применение ингибиторов fubp1 для лечения инфекции вирусом гепатита в | |
| WO2012174224A2 (en) | Methods for administering nucleic acid-based therapeutics | |
| JP2024544532A5 (enExample) | ||
| CN115702006A (zh) | 缀合基团及其缀合物 | |
| JP2023553610A5 (enExample) | ||
| CN108210510B (zh) | 一种小干扰核酸药物组合物及其用途 | |
| KR101783444B1 (ko) | miR-33-5p 를 이용한 뇌신경세포 보호 물질 스크리닝 방법 | |
| JP2018512140A5 (enExample) |